© 2020 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
November 29, 2019
A new report outlines the sharp cost increase associated with a NSCLC drug’s move from second-line to first-line treatment, and suggests payers work with manufacturers to address treatment pricing.
Chemotherapy may be the “boomer” to millennial-esque new cancer treatments, but there is a reason the old standard became that way, and isn’t likely to be replaced anytime soon.
November 25, 2019
There are a lot of ideas about ways to increase the value of cancer care, but personalized treatments may be the most significant and immediate.
A holistic approach provides value and creates plans that support the wide-ranging needs of cancer patients and their families.